Market Alert: ASX200 at Critical Support – Reversal or Further Fall?
Avecho Biotechnology Limited (ASX: AVE) has entered a ten-year exclusive licensing and development agreement with Sandoz Group AG for its Phase III cannabidiol (CBD) capsule targeting insomnia in Australia. Under the deal, Avecho will receive an upfront payment of US$3 million (~AU$4.8 million), along with US$16 million in development milestones and tiered royalties of 14%–19% on net sales. Sandoz will oversee the product’s commercialization, including marketing and distribution, while Avecho retains global rights, with Sandoz holding a right of first refusal for other markets.
The CBD capsule aims to be the first over-the-counter CBD product registered with the Therapeutic Goods Administration (TGA), addressing a market projected to exceed US$125 million annually. Avecho CEO Dr. Paul Gavin emphasized the partnership’s significance, highlighting Sandoz’s extensive market reach. Further details will be discussed in an investor webinar on March 4, 2025.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com
Apr 16, 2025
Apr 16, 2025
Apr 16, 2025
Apr 16, 2025
Apr 16, 2025
Apr 16, 2025
Apr 16, 2025
Apr 16, 2025
Apr 16, 2025
Apr 15, 2025
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
